NPC Archive Item: Does adding in tocilizumab to DMARDs help in rheumatoid arthritis (TOWARD study)?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Tocilizumab plus DMARDs was more effective than DMARDs alone at increasing ACR20 response rates in patients with moderate to severe rheumatoid arthritis who had experienced an inadequate response to […]

NPC Archive Item: Publication bias identified for drugs receiving U.S licensing approval

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. North American authors of an observational study have found evidence of incomplete and selective publication of clinical trials that supported successful licence applications to the FDA during the time […]

NPC Archive Item: Liraglutide plus metformin data from the LEAD-2 Met trial

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). […]

NPC Archive Item: Department of Health consultation on draft guidance for NHS patients who wish to pay for additional private care

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Department of Health. Draft guidance on NHS patients who wish to pay for additional private care — a consultation This draft guidance constitutes part of the government’s response to […]

NPC Archive Item: Early days for alemtuzumab▼ in early MS

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The CAMMS223 Trial Investigators. Alemtuzumab▼ vs. Interferon Beta-1a in Early Multiple Sclerosis. N Engl J Med 2008; 359:1786-801 Compared with interferon beta-1a, alemtuzumab▼ reduced the annualised risk of relapse and sustained […]

NPC Archive Item: Tocilizumab plus methotrexate studied in refractory RA (RADIATE)

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Emery P et al. Annals of the Rheumatic Diseases 2008;67:1516–1523 Tocilizumab with methotrexate was more effective than placebo and methotrexate at increasing ACR20 response rates in patients with moderate […]

NPC Archive Item: Olanzapine long-acting injection for schizophrenia

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. EMEA Summary of Positive Opinion for olanzapine long-acting injection (Zypadhera ®) In September 2008, the Committee for Medicinal Products for Human Use (CHMP) recommended European licensing approval of olanzapine […]

NPC Archive Item: Does liraglutide LEAD the way for monotherapy in patients with type2 diabetes mellitus?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Garber A, Henry R, Ratner R et al for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, […]

NPC Archive Item: Prasugrel in patients with diabetes mellitus

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Wiviott SD, et al for the TRITON-TIMI 38 Investigators. Circulation 2008. Prasugrel has a proposed indication for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) […]

NPC Archive Item: Once weekly vs twice daily exenatide▼ in the DURATION-1 trial

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Drucker DJ, Buse JB, Taylor K et al for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, […]